Nucana Plc ADR (NCNA)

$1.87 +0.01 (0.54%)
Market Cap 8.20M
Revenue (ttm) 0.00
Net Income (ttm) -38.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,779
Avg Vol 43,892
Day's Range N/A - N/A
Shares Out 4.16M
Stochastic %K 7%
Beta 2.17
Analysts Strong Buy
Price Target $25.00

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 13 1357 1111
Address:
3 Lochside Way, Edinburgh, United Kingdom
bills7765
bills7765 May. 13 at 12:52 PM
$NCNA I cant imagine many retail would vote yes for dilution. Moreover, I bet Kay is seeing a lot of NO votes for his return seeing how he has done absolutely nothing to create value. Hopefully they are seeing retails dissatisfaction with real time votes as they come in. I voted No for everything except keeping hugh in place. I trust the science, not the board at this point.
2 · Reply
Baseball89
Baseball89 May. 13 at 7:54 AM
$NCNA Sounds like Big news is coming
0 · Reply
GreenEnergy1
GreenEnergy1 May. 12 at 10:25 PM
$NCNA How’s everyone enjoying us selling our shares! Told you we’d tank this stock with our investment. p.s. We’re not done selling!
2 · Reply
bills7765
bills7765 May. 12 at 3:59 PM
$NCNA citi closed position as well
1 · Reply
bills7765
bills7765 May. 12 at 3:29 PM
$NCNA who are these guys? Lmao
1 · Reply
Spc_baller
Spc_baller May. 12 at 3:13 PM
$NCNA vote
1 · Reply
nkalargyros
nkalargyros May. 12 at 5:41 AM
$NCNA believe
0 · Reply
TVanda00
TVanda00 May. 11 at 4:57 PM
$NCNA I am turning into the ultra bull. process is playing out
1 · Reply
TVanda00
TVanda00 May. 11 at 4:57 PM
$NCNA nice bounce off of support
0 · Reply
chapelp
chapelp May. 11 at 4:44 PM
$NCNA where the F@K is SEC ?! this POS went from $13,000 to $1 in five years and it's still listed !?
0 · Reply
Latest News on NCNA
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

Mar 19, 2026, 4:01 PM EDT - 7 weeks ago

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana appoints Bruce as COO

2026-01-06T13:16:19.000Z - 4 months ago

NuCana appoints Bruce as COO

NuCana Appoints Theresa Bruce as Chief Operating Officer

Jan 6, 2026, 8:00 AM EST - 4 months ago

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana presents latest clinical data at ESMO 2025 on NUC-7738

2025-12-10T13:15:35.000Z - 5 months ago

NuCana presents latest clinical data at ESMO 2025 on NUC-7738

NuCana presents data at ESMO on NUC-7738

2025-12-10T13:05:39.000Z - 5 months ago

NuCana presents data at ESMO on NUC-7738

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Dec 10, 2025, 8:00 AM EST - 5 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 6 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana announces grant of composition-of-matter patent for NUC-7738 in China

2025-11-05T13:15:29.000Z - 6 months ago

NuCana announces grant of composition-of-matter patent for NUC-7738 in China

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Nov 5, 2025, 8:00 AM EST - 6 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitors

2025-10-19T21:10:12.000Z - 7 months ago

NuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitors

NuCana announces publication of new data for NUC-3373

2025-10-14T12:16:01.000Z - 7 months ago

NuCana announces publication of new data for NUC-3373

NuCana compliant with all Nasdaq continued listing criteria

2025-09-05T12:10:43.000Z - 8 months ago

NuCana compliant with all Nasdaq continued listing criteria

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 5, 2025, 8:00 AM EDT - 8 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Sep 3, 2025, 8:00 AM EDT - 9 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 20, 2025, 4:05 PM EDT - 9 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

NuCana PLC (ADR) trading halted, news pending

2025-08-08T23:50:31.000Z - 9 months ago

NuCana PLC (ADR) trading halted, news pending

NuCana announces ADS ratio change

2025-08-01T20:10:41.000Z - 10 months ago

NuCana announces ADS ratio change

NuCana Announces ADS Ratio Change

Aug 1, 2025, 4:05 PM EDT - 10 months ago

NuCana Announces ADS Ratio Change

NuCana cancels all outstanding Series A Warrants

2025-07-21T12:28:02.000Z - 10 months ago

NuCana cancels all outstanding Series A Warrants

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 21, 2025, 8:05 AM EDT - 10 months ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

NuCana Announces Plan to Implement ADS Ratio Change

Jul 11, 2025, 10:30 AM EDT - 10 months ago

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Jun 2, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

NuCana prices 10.8M ADSs at 64.54c in registered direct offering

2025-05-06T12:42:54.000Z - 1 year ago

NuCana prices 10.8M ADSs at 64.54c in registered direct offering

NuCana files to sell 16.05M American Depositary Shares

2025-04-24T10:21:56.000Z - 1 year ago

NuCana files to sell 16.05M American Depositary Shares

NuCana reports Q4 loss per share GBP (0.01) vs GBP (.14)

2025-03-20T20:55:23.000Z - 1 year ago

NuCana reports Q4 loss per share GBP (0.01) vs GBP (.14)

NuCana Reports Q4 EPS GBP (1) vs. GBP (14)

2025-03-20T20:20:12.000Z - 1 year ago

NuCana Reports Q4 EPS GBP (1) vs. GBP (14)

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year

2024-11-25T12:05:13.000Z - 1 year ago

NuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

2024-11-11T12:12:48.000Z - 1 year ago

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana price target lowered to $20 from $150 at Truist

2024-10-15T12:41:37.000Z - 1 year ago

NuCana price target lowered to $20 from $150 at Truist

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 8:36 AM EDT - 2 years ago

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 2 years ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 1, 2024, 4:01 PM EDT - 2 years ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

NuCana to Present at the Jefferies London Healthcare Conference

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

NuCana to Present at the Jefferies Healthcare Conference

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Receipt of Nasdaq Notice

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

NuCana to Participate in Two Upcoming Investor Conferences

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

NuCana Announces Receipt of NASDAQ Notice

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 6, 2022, 8:00 AM EDT - 4 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Aug 31, 2022, 8:00 AM EDT - 4 years ago

NuCana to Participate in Citi's 17th Annual BioPharma Conference

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 17, 2022, 4:01 PM EDT - 4 years ago

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

bills7765
bills7765 May. 13 at 12:52 PM
$NCNA I cant imagine many retail would vote yes for dilution. Moreover, I bet Kay is seeing a lot of NO votes for his return seeing how he has done absolutely nothing to create value. Hopefully they are seeing retails dissatisfaction with real time votes as they come in. I voted No for everything except keeping hugh in place. I trust the science, not the board at this point.
2 · Reply
Baseball89
Baseball89 May. 13 at 7:54 AM
$NCNA Sounds like Big news is coming
0 · Reply
GreenEnergy1
GreenEnergy1 May. 12 at 10:25 PM
$NCNA How’s everyone enjoying us selling our shares! Told you we’d tank this stock with our investment. p.s. We’re not done selling!
2 · Reply
bills7765
bills7765 May. 12 at 3:59 PM
$NCNA citi closed position as well
1 · Reply
bills7765
bills7765 May. 12 at 3:29 PM
$NCNA who are these guys? Lmao
1 · Reply
Spc_baller
Spc_baller May. 12 at 3:13 PM
$NCNA vote
1 · Reply
nkalargyros
nkalargyros May. 12 at 5:41 AM
$NCNA believe
0 · Reply
TVanda00
TVanda00 May. 11 at 4:57 PM
$NCNA I am turning into the ultra bull. process is playing out
1 · Reply
TVanda00
TVanda00 May. 11 at 4:57 PM
$NCNA nice bounce off of support
0 · Reply
chapelp
chapelp May. 11 at 4:44 PM
$NCNA where the F@K is SEC ?! this POS went from $13,000 to $1 in five years and it's still listed !?
0 · Reply
TVanda00
TVanda00 May. 11 at 4:17 PM
$NCNA
0 · Reply
Spc_baller
Spc_baller May. 11 at 3:18 PM
$NCNA
0 · Reply
TexasHeart
TexasHeart May. 10 at 6:13 AM
$NCNA May presentation now available: https://ir.nucana.com/static-files/ca508b6a-f34d-493f-8edf-bec4f7286614
2 · Reply
GI812
GI812 May. 10 at 12:44 AM
$NCNA We should get a report back in August on the compound drug trials. I'm hangin in at least until then.
0 · Reply
lffld
lffld May. 9 at 8:35 PM
$NCNA can you provide a link?
2 · Reply
checkthef
checkthef May. 9 at 7:09 AM
$NCNA carlyle closed 133k position
1 · Reply
cycloon
cycloon May. 8 at 3:59 PM
$NCNA
0 · Reply
FickleFin
FickleFin May. 8 at 12:31 PM
$NCNA only retail trades. Dead horse here.
1 · Reply
Chotchkiesflair37
Chotchkiesflair37 May. 7 at 6:03 PM
$NCNA @Docbrooks any thoughts with the AGM? I value your input
1 · Reply
bills7765
bills7765 May. 7 at 4:53 PM
$NCNA massive amounts of ftds.
2 · Reply
ChickenClaw
ChickenClaw May. 7 at 4:12 PM
$NCNA Anybody Back Out The 4Hr Chart To About January?....
0 · Reply
ChickenClaw
ChickenClaw May. 7 at 4:09 PM
$NCNA If They Sell New Shares Wont That Make More Cash On Hand? I Guess Unless They Are Gonna Build A Factory...If They Sell Shares To Buddies, Is It For The Buddies To Lose Money???? Dont Most Companies Try And Have Shelfs Set Up So They Dont Have To Try And Borrow In Future From These High Interest "Banks" If Needed.....Like They Said After All Of This Share Structure Downsizing They Said That They Must Re submit A Organizatioanl Game Plan?
1 · Reply